中粮科技(000930) - 2022 Q1 - 季度财报

Financial Performance - Revenue for Q1 2022 was CNY 5,380,135,205.78, a decrease of 4.26% compared to CNY 5,619,402,840.05 in the same period last year[3] - Net profit attributable to shareholders was CNY 348,969,121.63, down 1.90% from CNY 355,745,352.30 year-on-year[3] - Total operating revenue for the current period is ¥5,380,135,205.78, a decrease of 4.26% from ¥5,619,402,840.05 in the previous period[26] - Net profit for the current period is ¥351,613,777.03, down 4.99% from ¥368,490,603.57 in the previous period[29] - The company reported a total comprehensive income of ¥339,459,236.62, down from ¥364,599,052.96 in the previous period[32] Cash Flow - Net cash flow from operating activities was negative CNY 63,556,964.26, a decline of 112.24% compared to CNY 519,066,471.27 in the previous year[3] - Cash flow from operating activities totaled ¥6,847,784,435.93, down 10.09% from ¥7,616,032,616.85 in the previous period[33] - The net cash flow from operating activities was -$63.56 million, a significant decrease compared to $519.07 million in the previous period[36] - Total cash outflow from operating activities amounted to $6.91 billion, slightly down from $7.10 billion year-over-year[36] - The net cash flow from investment activities was -$232.88 million, improving from -$287.26 million year-over-year[36] - Cash inflow from financing activities totaled $1.93 billion, down from $3.44 billion in the previous period[36] - The net cash flow from financing activities was $515.49 million, compared to $601.57 million in the prior year[36] - The ending cash and cash equivalents balance was $1.33 billion, down from $1.48 billion year-over-year[36] Assets and Liabilities - Total assets increased by 4.62% to CNY 18,897,067,009.31 from CNY 18,062,119,861.99 at the end of the previous year[3] - Current assets amounted to RMB 8,490,911,961.52, up from RMB 7,634,382,643.86 at the beginning of the year, reflecting a growth of approximately 11.25%[19] - Total liabilities reached RMB 6,795,200,779.60, compared to RMB 6,303,423,281.92 at the beginning of the year, marking an increase of approximately 7.8%[22] - The company’s non-current assets totaled RMB 10,406,155,047.79, slightly down from RMB 10,427,737,218.13, indicating a decrease of approximately 0.2%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 132,711[12] - The largest shareholder, COFCO Bio-chemical Investment Co., Ltd., holds 47.34% of the shares, totaling 883,233,262 shares[12] - Shareholders' equity attributable to the parent company rose by 2.99% to CNY 11,737,714,385.35 from CNY 11,397,350,949.32[3] - The company's equity attributable to shareholders increased to RMB 11,737,714,385.35 from RMB 11,397,350,949.32, reflecting a growth of about 2.98%[25] Research and Development - Research and development expenses increased by 51.01% to CNY 39,032,316.59 from CNY 25,847,519.63 year-on-year[7] - Research and development expenses increased to ¥39,032,316.59, up 51.06% from ¥25,847,519.63 in the previous period[26] Other Income and Expenses - Other income surged by 3518.25% to CNY 246,188,806.58, primarily due to increased government subsidies from asset disposals[7] - Other income increased significantly to ¥246,188,806.58 from ¥6,804,076.22, marking a substantial rise[26] - Investment income decreased by 127.89% to negative CNY 9,237,987.17, mainly due to losses from derivatives and investments in associates[7] - Investment losses amounted to ¥9,237,987.17, compared to a gain of ¥33,126,894.63 in the previous period[26]